Recent advances in basic medical research and clinical therapeutics have optimized the application of glucagon-like peptide-1 (GLP-1), establishing it as a cornerstone incretin based therapy for T2DM management. The gene discussed is GCG; the disease is type 2 diabetes mellitus.